-
2021 ASCO Locally advanced MIBC: When will dual immunity + radiotherapy replace cystectomy?
Time of Update: 2021-06-22
The IMMUNOPRESERVE-SOGUG study explored the results of dual immunotherapy + simultaneous radiotherapy for locally advanced muscle invasive bladder cancer (MIBC) .
T2-4a N0 M0 stage locally advanced MIBC, ECOG 0~1, no contraindications to immunotherapy, intentional bladder retention or unsuitable for cystectomy were included in the study .
-
[2021 ASCO] The importance of early new endocrine therapy for mHSPC patients from the TITAN study on the quality of life of patients
Time of Update: 2021-06-22
*For medical professionals' reference only, the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021) will be held online from June 4 to 8, 2021 . As one of the largest and largest a
-
Evidence-based guidelines, advancing with the times-2021 version of "CSCO Prostate Cancer Diagnosis and Treatment Guidelines" is officially released!
Time of Update: 2021-06-18
In the press conference, Professor Zhu Yao from the Cancer Hospital of Fudan University shared the revision process of the CSCO prostate cancer diagnosis and treatment guidelines, and specifically pointed out the updated principles and characteristics of the guidelines: evidence-based medicine, keeping pace with the times; precision medicine, Diagnosis goes first; medicines are available, treatment value; local data, leading guidelines .
-
Erectile dysfunction may be related to cardiovascular disease?
Time of Update: 2021-06-02
What are the risk factors for atherosclerotic cardiovascular disease (ASCVD)?
ED and cardiovascular diseases share common risk factors, such as obesity, hypertension, metabolic syndrome, diabetes, and smoking.
3. ED should be regarded as a risk factor for cardiovascular disease.
-
Shandong University Zou Yongxin/Shi Benkang discovered the potential new mechanism of bladder cancer metastasis
Time of Update: 2021-06-02
In summary, the study found that the key role of the FOXA1-KDM6A-ARHGDIB axis in suppressing BCa malignancies has been established, and KDM6A and EZH2 have been identified as potential therapeutic targets in the management of BCa.
-
The latest 5-point cancer methylation article published
Time of Update: 2021-06-02
In order to find biomarkers and risk stratification that are independent of clinical features to diagnose diseases and reduce overtreatment, this paper conducts leukocyte whole-genome DNA methylation analysis on 287 PCa (GS=6, GS≥8), by constructing 5 times Cross-validation of the random forest model, screening a methylation model containing 97 DMPs (AUC=0.
-
A case of ureteral obstruction with peak circuit turn
Time of Update: 2021-06-01
In most cases of non-small cell lung cancer with secondary ureteral metastasis, because the early symptoms of ureteral metastasis may be masked by the primary tumor or other metastases, or because the patient’s general condition is not good, the clinician has not been able to precede the death of the patient.
-
Clinical Essentials | Overview of Ultrasound Manifestations of Kidney Stones and Ureteral Stones
Time of Update: 2021-06-01
2. Large stones occupying the central echo (renal sinus) area are called coral stones.
10 Ureteral stones (transition of renal pelvis and ureter) Fig.
12 Ureteral stones (transition of ureter and bladder) Fig 13 Extravasation of renal pelvis Clinical 1.
-
Professor Ye Dingwei: Interpretation of the updated points of the CSCO prostate cancer diagnosis and treatment guidelines of the 2021 edition
Time of Update: 2021-05-22
Based on the above evidence, the 2021 version of the CSCO prostate cancer guidelines for patients with metastatic prostate cancer for the purpose of making treatment decisions, the genetic testing type III recommended a new TP53, and a new tumor tissue + plasma ctDNA sample for the test sample type (I Grade/II recommendation).
-
An overview of the article: Interpretation of the key points of the 2021 CSCO Urinary Oncology Guidelines Update
Time of Update: 2021-05-22
In the first-line treatment of the new CSCO guidelines for urothelial cancer, for patients with locally advanced or metastatic urothelial cancer that are not suitable for cisplatin, the level III recommendation still retains atezizumab (class 2A evidence) and pembrolizumab Monoclonal antibody (Class 2A evidence).
-
2021 AACR | Dual immunotherapy is first effective in treated mCPRC patients!
Time of Update: 2021-05-22
At this AACR conference, researchers announced the efficacy and safety of nivolumab + ipilimumab in the NEPTUNES study cohort 1 for ImS + mCRPC.
Results: A total of 211 patients were screened, 50 of which were ImS positive, 35 patients received nivolumab + ipilimumab, the median follow-up time was 7.
-
Prof. Cui Chuanliang: Interpretation of the key points of the 2021 CSCO Urothelial Carcinoma Diagnosis and Treatment Guidelines Update
Time of Update: 2021-05-22
In the first-line treatment of the new CSCO guidelines for urothelial cancer, for patients with locally advanced or metastatic urothelial cancer that are not suitable for cisplatin, the level III recommendation still retains atezizumab (class 2A evidence) and pembrolizumab Monoclonal antibody (Class 2A evidence).
-
Molecular Cancer | 2 articles in a row!
Time of Update: 2021-05-10
In conclusion, the study found that CircLIFR may interact with MSH2 and positively regulate CDDP sensitivity in bladder cancer through the MutSα/ATM-p73 axis.
Subsequent studies have shown that circLIFR can interact with MSH2 and positively regulate CDDP sensitivity in bladder cancer cell lines through the MutSα/ ATM-p73 axis.
-
Talazoparib used in BRCA2 germline mutant mCRPC patients has an ORR of 50%!
Time of Update: 2021-05-10
1, and may be sensitive to PARP inhibitors (ATM, ATR, BRCA1, BRCA2, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C) DNA damage response mutation (tDDRalt) in patients with metastatic castration-resistant prostate cancer (mCRPC).
-
PNAS: SUSTech Hu Hailiang team and others reveal the metabolic mechanism of prostate cancer progression and treatment resistance
Time of Update: 2021-05-10
In general, the study reported a new molecular metabolic mechanism of prostate cancer resistance to hormone therapy, which has a huge promotion effect on the diagnosis and treatment of prostate cancer.
-
Major update of ASCO guidelines: Recommended initial treatment for metastatic non-castrated prostate cancer
Time of Update: 2021-05-10
4: For patients with high-risk new-onset metastatic non-castrated prostate cancer, according to the LATITUDE study, ADT+Abiraterone can be given (Type: evidence-based, the advantages outweigh the disadvantages; the quality of evidence: high; the strength of the recommendation: LATITUDE Patients with high-risk diseases defined by the study are strong).
-
Dialogue with Professor Yang Yong: Abiraterone helps prostate cancer patients "full process" benefit | Choose the power of "Ze"
Time of Update: 2021-05-10
"Professor Yang Yong leads his "small" team to keep up with the international "trend" of prostate cancer treatment, master the experience of using new drugs and new treatment methods, and provide patients with better services.
-
Someone in the family has prostate cancer, how can others reduce the risk?
Time of Update: 2021-05-09
After adjusting for other factors, the researchers found that people with high genetic risk are more likely to develop prostate cancer; and adhering to a healthy life>Compared with the 1/4 subjects with the lowest polygenic risk score for prostate cancer, the 1/4 subjects with the highest score were associated with a 439% increase in the risk of prostate cancer and a 243% increase in the risk of fatal prostate cancer.
-
Dialogue with Professor Hou Sichuan: Abiraterone helps the long-term survival of prostate cancer patients|The power of choosing "Ze"
Time of Update: 2021-05-09
As the director of the Department of Urology at Qingdao Municipal Hospital, Professor Hou Sichuan has treated countless prostate cancer patients and has extensive clinical experience.
-
2021 edition of CSCO prostate cancer diagnosis and treatment guidelines update key points: attention to detail, precise treatment
Time of Update: 2021-05-09
Based on the above evidence, the 2021 version of the CSCO PC guidelines: the type of patients for the purpose of making treatment decisions is metastatic prostate cancer, the level III recommendation of the test type adds TP53, and the test sample type is updated to tumor tissue + plasma ctDNA sample.
